atezolizumab,oxaliplatin,5-fluorouracil,l-leucovorin,bevacizumab,irinotecan
roche
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'atezo', 'atezotribe', 'rectal', 'colorectal']
colorectal oral abstracts begin! updated results of phase ii atezotribe presented by dr. antoniotti: folfoxiri/bev +/- atezo in mcrc (all comers): pfs 13.1 vs 11.5 months, os 33 vs 27 months (hr 0.81, p=0.136) #asco23 
Medical oncologist: GI cancers & cancer of unknown primary + high quality & value-based cancer care delivery. @UTexasValue MSHCT student. Tweets mine.